We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Netscientific Plc | LSE:NSCI | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 63.00 | 61.00 | 65.00 | 63.00 | 63.00 | 63.00 | 135 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1M | -3.09M | -0.1312 | -4.80 | 14.85M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/6/2021 12:39 | Sorry but is NSCI listed in USA? Surely not!! | billthebank | |
07/6/2021 12:35 | it certainly be interesting afternoon once the US markets open :-) | ak62 | |
07/6/2021 12:34 | for those that didn't know: How can serology test be helpful in understanding the COVID-19 pandemic? Serologic tests measure the antibody response in an individual. Antibodies to COVID-19 are produced over days to weeks after infection with the virus. The presence of antibodies indicates that a person was infected with the COVID-19 virus, irrespective of whether the individual had severe or mild disease, or even asymptomatic infection. Surveillance of antibody seropositivity in a population can allow inferences to be made about the extent of infection and about the cumulative incidence of infection in the population. The use of serology in epidemiology and public health research enables understanding of: • the occurrence of infection among different populations; • how many people have mild or asymptomatic infection, and who may not have been identified by routine disease surveillance; • the proportion of fatal infections among those infected; • the proportion of the population who may be protected against infection in the future so having a global agreement is a big deal: NetScientific chief executive Dr Ilian Iliev: “The assay could if fully validated potentially attract a substantial market." | kalkaar | |
07/6/2021 12:31 | USA buying must come into play as their working business day timescale comes around and the NSCI news really gets some broad exposure. f | fillipe | |
07/6/2021 12:21 | loaf, lol i agree with what you and a few others have said earlier that had this deal been done with some of the other listed companies they would have doubled by now.. maybe the stock is too tight to get hold of not just under the radar.. i would say that's one of the few attractions of having such a small free float.. when the shares move it doesn't take much to bid them up (obviously vice versa also applies) | kalkaar | |
07/6/2021 12:20 | here we go on the move- here comes 150p | ak62 | |
07/6/2021 12:13 | I've put it on the GME/AMC feed on that funny app thing so should be about 6M reading it in about an hours time. | loafofbread | |
07/6/2021 12:08 | 110p at the live lowest ASK as I type. f | fillipe | |
07/6/2021 12:02 | when full details emerge on the deal this is sure to ignite the shares again because i'm not sure everyone fully understands (me included) the enormity of the agreement as yet: Ruth March, SVP, Precision Medicine, AstraZeneca said: “The development of this serology ELISA by our team is another example of AstraZeneca’s comprehensive response to the COVID-19 pandemic. This highly sensitive and specific blood test makes use of simple and convenient fingerstick sample collection that will be well suited to large scale deployment and has the potential to play an important role in antibody analyses in large populations.” Dr David Ribeiro, CEO of ProAxsis, commented: “We’re excited to be involved with this assay to support such a key area of global healthcare need. The research team at AstraZeneca have already completed significant optimisation and validation work, which has demonstrated the assay’s high potential sensitivity and specificity of detecting SARS-CoV-2 antibodies. ProAxsis will extend this work to support the identification of people who have raised antibodies against this challenging virus.” | kalkaar | |
07/6/2021 11:42 | Hmmm Great RNS. Co only valued at £15M Has a holding in an American Co worth £10.5M so yup even at 111 it looks like a great opportunity for more growth? | billthebank | |
07/6/2021 11:28 | next stop 150p | ak62 | |
07/6/2021 11:19 | That'll teach them!! | blakieboy7 | |
07/6/2021 11:18 | Schroders: oh Dear! they had close on 9% of NSCI up until 3 weeks ago.. apparently their holding was sitting in the wrong fund type and rather than transfer the holding into the correct fund (smaller co/growth fund) they just decided to offload and be done with them! just goes to show even institutions can royally screw up from time to time.. | kalkaar | |
07/6/2021 11:08 | This is just the start!! | blakieboy7 | |
07/6/2021 11:07 | WH Ireland was wrong even when published . But useful benchmark for non-PDSB. We await their update !! | bertiebingo | |
07/6/2021 11:04 | loafofbread 7 Jun '21 - 11:00 - 3067 of 3067 ____________________ :D | kalkaar | |
07/6/2021 11:03 | Brilliant rises but long way to go.... Thoughts on 1.40 at close today? | samsung2020 | |
07/6/2021 11:00 | Flys out of auction. Only £14 to go. | loafofbread | |
07/6/2021 10:59 | 1.0755 to sell 1.095 to buy should smash +50% very soon | ak62 | |
07/6/2021 10:54 | Should have much much further to go. | investordave | |
07/6/2021 10:53 | Every shake is being smashed! | chesty1 | |
07/6/2021 10:40 | Bucking bronco!! Theyre shaking this one. Hang on rodeo. | escapetohome | |
07/6/2021 10:32 | 150p inbound then 200p initial target.Massive update.Investors realising the potential. | 36jay |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions